TIGIT and neoplasm: To address the involvement of these two types of cells in mediating the anti-tumor activity of VV-α-TIGIT, we depleted either CD8+ T or NK cells of mice and analyzed the impact of the depletion of these two types of cells on the therapeutic benefit by monitoring survival in H22 ascites tumor model (Fig. 7A).